Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

America’s obesity crisis extends beyond humans — studies suggest that around 60% of dogs and cats nationwide are overweight.

A host of women have complained that they are experiencing 'Ozempic vulva' after taking weight loss drugs to shed the pounds.

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

GLP-1 weight-loss drugs are creating “mortality slippage” in life insurance which is a costly problem that's forcing insurers to rethink how they underwrite.

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes patients ...

An international clinical trail showed the risk of kidneys deteriorating or failing was lower in patients taking Ozempic, as ...